Dilip Bhat, Jt MD of Prabhudas Lilladher, says from the pharma pack, Ranbaxy really looks good and in the multinational space GlaxoSmithKline and Pfizer looks very solid. In the midcap space, Divis Labs can give phenomenal returns in 2-3 years period.